Karuna Therapeutics, a Phase 2 biotech developing therapies for schizophrenia and other CNS disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Boston, MA-based company was founded in 2009 and plans to list on the Nasdaq under the symbol KRTX. Karuna Therapeutics filed confidentially on March 29, 2019. Goldman Sachs, Citi and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.